QIAGEN Teams with China’s Lepu Medical to Provide Rapid Diagnosis of Heart Attacks Using Point of Need Testing

BEIJING, China, and HILDEN, Germany, September 13, 2012 /PRNewswire/ –

        - QIAGEN's cutting-edge ESEQuant Lateral Flow System will run Lepu Medical's
          tests for key cardiac biomarkers to deliver lifesaving information in emergency rooms
        - Cardiac testing adds further momentum for QIAGEN in fast-growing Chinese
          market
        - Pioneering ESEQuant platform achieves first regulatory approval in human
          healthcare, expanding QIAGEN's global Point of Need business

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced an agreement
with Lepu Medical Technology (Beijing) Co., Ltd., a leading medical device company in
China, to provide QIAGEN’s ESEQuant Lateral Flow System for use in emergency rooms with
Lepu’s tests for cardiac markers that diagnose acute myocardial infarction (heart attack).
The agreement expands QIAGEN’s presence in China and adds a new point of need diagnostics
application.

China’s State Food and Drug Administration (SFDA) has approved the ESEQuant Lateral
Flow detection system with Lepu Medical’s five cardiac marker tests. Lepu will market the
system in China under the name LEPU Quant-Gold. Globally, this is the first regulatory
approval in human healthcare for QIAGEN’s pioneering ESEQuant platform which was acquired
in 2010.

“We are very pleased to begin this relationship with the Lepu Group and meet a
pressing need for heart patients by combining ESEQuant’s quick turnaround time with the
reliability of Lepu’s tests for cardiac biomarkers,” said Dr. Frank Krieg-Schneider, Head
of Global Strategic Alliances & OEM at QIAGEN. “This agreement advances two strategic
initiatives: First, our geographic presence is further broadened by the addition of
important point of need assays in China. China today represents QIAGEN’s third-largest
country in sales. Secondly, we are driving platform success by launching ESEQuant as an
SFDA-approved device in a lifesaving medical application, a milestone for our emerging
Point of Need portfolio.”

QIAGEN’s Point of Need portfolio is rapidly expanding. The growth is based on the
benefits of the revolutionary ESE platform portfolio as well as on the value of the
pipeline and portfolio of molecular and other assays for these platforms. Earlier in 2012
QIAGEN acquired the AmniSure immunoassay for rupture of amniotic membranes in pregnant
women, a self-contained test used in doctor’s offices and maternity units, and joined a
global initiative with the Bill and Melinda Gates Foundation to create much-needed
platforms for point of care diagnosis in the developing world. “Our vision for point of
need is to bring the speed and reliability of advanced diagnostics into emergency rooms,
physician offices and other places where care is given without immediate access to
laboratories”, Dr. Krieg-Schneider added.

The agreement with Lepu Medical begins with shipment of 750 ESEQuant systems for China
and is expected to grow. The need in emergency rooms is for quick response with
appropriate treatments, since patients suffering heart attacks face the greatest risk of
death in the first hour. Currently, ambulance personnel take samples to test for cardiac
markers, and upon arrival at the hospital these are sent to a laboratory – a delay of an
hour or more. QIAGEN’s ESEQuant platform will run Lepu’s tests to measure key cardiac
markers immediately after the ambulance arrives at the emergency room, allowing accurate
diagnosis within minutes at the point of care – a lifesaving improvement. China has more
than 14,000 public hospitals and an additional 5,700 private hospitals, according to 2009
public data.

As QIAGEN continues to expand its presence in China, the Lepu Medical relationship
builds upon other major instrument supply agreements, including Hangzhou Proprium Biotech
Co., Ltd. in the field of cancer diagnostics.

About Lepu:

Established in 1999, Lepu Medical Technology (Beijing) Co., Ltd. is specialized in
high-tech medical device development, production and sales. Lepu has built up a leading
group company concentrating in cardiac therapy, with products including interventional
cardiology, occlusion devices, prosthetic heart valves, pacemaker, cardiac in vitro
diagnosis products, angiographic equipment and anesthetic products. In October 2009, Lepu
successfully listed on ChiNext of Shenzhen Stock Exchange market (stock symbol 300003:
CH).

About QIAGEN:

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample &
Assay Technologies that are used to transform biological materials into valuable molecular
information. Sample technologies are used to isolate and process DNA, RNA and proteins
from biological samples such as blood or tissue. Assay technologies are then used to make
these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than
500 products around the world, selling both consumable kits and automation systems to
customers through four customer classes: Molecular Diagnostics (human healthcare), Applied
Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and
biotechnology companies) and Academia (life sciences research). As of June 30, 2012,
QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further
information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended.
To the extent that any of the statements contained herein relating to QIAGEN’s products,
markets, strategy or operating results, including without limitation its expected
operating results, are forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks. Such uncertainties and
risks include, but are not limited to, risks associated with management of growth and
international operations (including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating results and allocations
between customer classes, the commercial development of markets for our products in
applied testing, personalized healthcare, clinical research, proteomics, women’s
health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships
with customers, suppliers and strategic partners; competition; rapid or unexpected changes
in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due
to general economic conditions, the level and timing of customers’ funding, budgets and
other factors); our ability to obtain regulatory approval of our products; difficulties in
successfully adapting QIAGEN’s products to integrated solutions and producing such
products; the ability of QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors’ products; market acceptance of QIAGEN’s new
products, the consummation of acquisitions, and the integration of acquired technologies
and businesses. For further information, please refer to the discussions in reports that
QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

        Contacts:

        Public Relations:
        Dr. Thomas Theuringer
        Director Public Relations
        +49-2103-29-11826
        +1-240-686-7425
        Email: pr@qiagen.com

http://www.twitter.com/qiagen

http://www.qiagen.com/about/press

        Investor Relations:
        John Gilardi
        VP Corporate Communications
        +49-2103-29-11711
        +1-240-686-2222

        Albert F. Fleury
        Investor Relations North America
        +1-240-686-7400
        Email: ir@qiagen.com

http://www.qiagen.com/about/investorrelation

SOURCE Qiagen N.V.